Tech

US health regulator approves anti-anxiety device from Belfast-based Neurovalens

Healthtech firm received FDA clearance in October for an anti-insomnia device and has approvals pending for the treatment of PTSD and obesity

Dr. Jason McKeown, Neurovalens CEO, said the FDA approval for Modius Stress represented the “next meaningful step” for the firm’s growth in the US. Picture: Neurovalens

Neurovalens, the Belfast-based healthtech startup, has received approval from the US Food & Drug Administration (FDA) for an electrical stimulation anti-anxiety device.

The firm’s Modius Stress device, designed to treat anxiety by delivering a small electrical pulse to the head for 30 minutes at night, can now be sold directly to sufferers of General Anxiety Disorder (GAD) in the United States who hold a prescription from a doctor.

Neurovalens announced that it had closed a ...